Press "Enter" to skip to content

Common osteoporosis drugs linked to 24% lower dementia risk in major study

Osteoporosis drugs are often given to prevent bone loss and reduce bone fractures. However, these drugs also have another interesting effect.

Specific osteoporosis drugs contain specific compounds known as nitrogen-containing bisphosphonates (NBPs). These compounds sever the ability of osteoclasts (cells that break down mineralized bone) to function.

A recent study by the University of Hong Kong Li Ka Shing Faculty of Medicine (HKUMed) took 121,492 adults above the age of sixty, all of whom had osteoporosis or “fragility fractures,” which are breaks in bones that occur after they have already weakened. Records covered the period between 2005 and 2020. After participants took these drugs, HKUMed researchers found that adults taking osteoporosis drugs with NBPs were actually 16% less likely to develop Alzheimer’s disease and Alzheimer’s Disease Related Dementias (ADRDs) than those taking no medication. Those taking other kinds of osteoporosis drugs (not containing NBPs) were 24% less at risk compared to adults receiving no medication. The strongest associations between treatments and lower risks of ADRDs were among women and those who had suffered hip fractures. Researchers also estimated that treating approximately 48 patients with osteoporosis drugs over a period of five years could prevent one case of ADRDs.

However, this test does not establish any causation between lower risks of ADRDs and NBPs; confirmation in a clinical trial would be required. “Generalizability is another consideration, as our study involved only a Chinese population, and it remains uncertain whether the findings apply to other populations,” said study author Chin-Leung Cheung, a pharmacology professor at HKUMed. One of the test’s other limitations was that individuals who already had ADRDs or other cognitive impairments were not given any treatments, so the test was not able to provide any results on the effectiveness of giving treatments to those who may already have ADRDs. Since no clinical trial has occurred, not enough justifiable evidence exists for prescribing NBPs to prevent ADRDs. No NBPs have specifically been made to prevent dementia or any other ADRDs, either. This is not to say NBPs are completely ineffective, however, as they fill a critical pathway for reducing the number of elderly individuals susceptible to ADRDs while dedicated treatments are still underway. Researchers continue to look at not only medications that are already widely in use, but also cost-effective treatments, and the use of NBPs satisfies both of these needs.

Photo Courtesy of eMedicineHealth.com